- Age [ Time Frame: Index date defined as the date of the earliest brolucizumab injection during the index period (from 08-Oct-2019 to 30-Apr-2020) ]
Age information was reported
- Gender information [ Time Frame: Index date defined as the date of the earliest brolucizumab injection during the index period (from 08-Oct-2019 to 30-Apr-2020) ]
Gender information was reported
- Number of patients at various Patient Region [ Time Frame: Index date defined as the date of the earliest brolucizumab injection during the index period (from 08-Oct-2019 to 30-Apr-2020) ]
Patient regions: Northeast, Midwest, South, West, Unknown
- Number of patients with Insurance type [ Time Frame: Index date defined as the date of the earliest brolucizumab injection during the index period (from 08-Oct-2019 to 30-Apr-2020) ]
Insurance type: Private, Medicare, Medicare Advantage, Medicaid, Other
- Number of patients with Laterality of wet Age-related macular degeneration (AMD) [ Time Frame: Index date defined as the date of the earliest brolucizumab injection during the index period (from 08-Oct-2019 to 30-Apr-2020) ]
Laterality of wet AMD: Unilateral, Bilateral
- Number of patients with Laterality of any Age-related macular degeneration (AMD) [ Time Frame: Index date defined as the date of the earliest brolucizumab injection during the index period (from 08-Oct-2019 to 30-Apr-2020) ]
Laterality of wet AMD: Unilateral, Bilateral
- Number of eyes with the concurrent eye disease [ Time Frame: Within 180 days prior to the index date (inclusive of the index date) ( index date defined as the date of first brolucizumab injection) ]
Types of concurrent eye diseases:
- Cataracts
- Posterior vitreous detachment
- Puckering of macula
- Macular hole
- Vitreomacular traction
- Glaucoma
- Amblyopia
- Papillitis
- Ischemic optic atrophy
- Diabetic retinopathy
- Diabetic macular edema
- Hypertensive retinopathy
- Pathologic myopia
- RAO
- RO
- RV
- Vitritis
- Endophthalmitis
- Uveitis
- Choroidal neovascularization (due to causes other than AMD, if possible, to determine)
- IOI
- Number of patient eyes with previous ocular surgeries or procedures [ Time Frame: Within 180 days prior to the index date (inclusive of the index date) ( index date defined as the date of first brolucizumab injection) ]
Types:
- Laser photocoagulation (or laser therapy)
- Photodynamic therapy (PDT)
- Glaucoma surgery (trabeculectomy, MIGS)
- Cataract surgery
- Iridotomy
- Ocular radiation
- Panretinal photocoagulation
- Submacular surgery, other surgical intervention or laser treatment for AMD
- Vitrectomy
- Scleral buckle
- Pneumatic retinopexy
- Cryopexy
- Number of patient eyes with systemic comorbidities [ Time Frame: 36-month period prior to the index date (inclusive of the index date) ( index date defined as the date of first brolucizumab injection) ]
Types:
- Obesity
- Cerebrovascular disease
- Peripheral vascular disease
- Diabetes
- Renal disease
- Chronic pulmonary disease
- Congestive heart failure
- Any malignancy, including lymphoma and leukemia
- Myocardial infarction
- Dementia
- Arteriothrombotic event
- Thromboembolytic event
- Atherosclerosis
- Arterial hypertension
- Ischemic heart disease
- Atrial fibrillation
- Lipid disorders
- Cardiac septal defect
- Valvular cardiac defect
- Hyperlipidemia
- Hypercholesterolemia
- Atherosclerotic disease
- Thrombosis
- Carotid artery disease
- Number of Concomitant systemic medications (chronic use) [ Time Frame: 36-month period prior to the index date (inclusive of the index date) ( index date defined as the date of first brolucizumab injection) ]
Types:
- Corticosteroids
- Systemic anti-VEGFs
- Lipid lowering agents
- Antihypertensives
- Biologics
- Antimetabolites/cancer therapy
- Anticoagulants
- Number of patient eyes with the Cataract status [ Time Frame: 36-month period prior to the index date (inclusive of the index date) ( index date defined as the date of first brolucizumab injection) ]
Types: phakic, pseudophakic, aphakic
- Number of patient eyes with Intraocular inflammation [ Time Frame: 12 and 6 months prior to the index date (inclusive of the index date) ( index date defined as the date of first brolucizumab injection) ]
The following categories were reported:
- No history of IOI and endophthalmitis related to safety evaluation and panuveitis
- History of IOI and endophthalmitis related to safety evaluation and panuveitis
- History of IOI including panuveitis (excluding endophthalmitis related to safety evaluation)
- History of endophthalmitis related to safety evaluation
- History of panuveitis
- Number of patient eyes with the history of ocular inflammation (includes IOIs or panuveitis or endophthalmitis relevant to safety evaluation) [ Time Frame: 36-month period prior to the index date (inclusive of the index date) ( index date defined as the date of first brolucizumab injection) ]
The following categories were reported:
- History of anterior inflammation
- History of posterior inflammation
- No history of IOI or endophthalmitis related to safety evaluation or panuveitis
- History of IOI and/or endophthalmitis related to safety evaluation and/or panuveitis
- History of IOI including panuveitis (excluding endophthalmitis related to safety evaluation)
- History of endophthalmitis related to safety evaluation
- History of Panuveitis
- History of other IOI and endophthalmitis due to infections or other underlying disease [ Time Frame: 36, 12 and 6 months prior to the index date (inclusive of the index date) ( index date defined as the date of first brolucizumab injection) ]
The following categories were reported:
- No history of inflammation
- History of any ocular inflammation
- History of severe ocular inflammation
- History of anterior inflammation
- History of posterior inflammation
- History of IOI or endophthalmitis due to infections and other underlying disease (separate category)
- Number of patient eyes with prior Intraocular Inflammation (IOI) and/or prior Retinal vascular occlusion (RO) [ Time Frame: 12 months prior to the index date ( index date defined as the date of first brolucizumab injection) ]
Included history of ocular inflammation or occlusion
- Number of patient eyes with Systemic inflammation / auto-immune history (in total and at the event level) [ Time Frame: 36-month period prior to the index date (inclusive of the index date) ( index date defined as the date of first brolucizumab injection) ]
The following categories were reported:
- Systemic vasculitis
- Rheumatoid arthritis
- SLE
- Multiple sclerosis
- Sarcoidosis
- Giant cell arteritis / Temporal arteritis
- HLA-B27 diseases
- Behcet/Behcet's disease
- Ankylosing Spondylitis
- Crohn Disease
- Drug Hypersensitivity
- Vogt-Koyanagi-Harada (VKH)
- Number of patient eyes with the Provider specialty [ Time Frame: Index date defined as the date of the earliest brolucizumab injection during the index period (from 08-Oct-2019 to 30-Apr-2020) ]
The following types were included:
Retina specialist, General ophthalmologist, Non-retina specialist, unknown
- Number of patient eyes with Concomitant ocular medications [ Time Frame: 36-month period prior to the index date (inclusive of the index date) ( index date defined as the date of first brolucizumab injection) ]
The following types were included: any corticosteroids [prednisone, prednisolone acetate, difluprednate, Kenalog, ozurdex, yutiq], biologics [adalimumab], cyclosporine, azathioprine, methotrexate, ganciclovir, acyclovir, valacyclovir, foscavir, trifluridine, mycophenolate, rituxan, vancomycin, prostaglandins
- Type of exam performed [ Time Frame: 30 days before or on first brolucizumab injection (index date) ]
OCT, FA, CP - color photo or color fundus photo
- Number of eyes treated with brolucizumab [ Time Frame: Index date defined as the date of the earliest brolucizumab injection during the index period (from 08-Oct-2019 to 30-Apr-2020) ]
The following types were included:
OD [eye, right], OS [eye, left], Unspecified, Unilateral, Bilateral)
- Number of patient eyes with Anti-VEGF treatment-naive vs prior-treated [ Time Frame: 60 months prior to index ( index date defined as the date of first brolucizumab injection) ]
Anti-VEGF treatment-naive vs prior-treated were measured at the eye-level
- Number of patient eyes with prior treatment status [ Time Frame: 60 months prior to index ( index date defined as the date of first brolucizumab injection) ]
The following types were included: off-label bevacizumab, ranibizumab, aflibercept, unknown, treatment-naive
- Number of patient eyes with different prior anti-VEGF agents [ Time Frame: 60 months prior to index ( index date defined as the date of first brolucizumab injection) ]
Following categories will be included : 0, 1, 2, ≥3
- Number of patient eyes with prior anti-VEGF agents (total, per anti-VEGF agent) [ Time Frame: 60 months prior to index ( index date defined as the date of first brolucizumab injection) ]
Following categories will be included :
- Continuous
- Categorical: <6, 6 to <12, 12 to <24, ≥24
- Number of patient eyes with the Last injection inetrval [ Time Frame: 60 months prior to index ( index date defined as the date of first brolucizumab injection) ]
Following categories will be included :
- Continuous (weeks)
- Categorical: <4, 4 to <6, 6 to <8, ≥8, <12, ≥12 weeks
- Duration of last anti-VEGF treatment (total, per anti-VEGF agent) [ Time Frame: 60 months prior to index ( index date defined as the date of first brolucizumab injection) ]
Following categories will be included :
- All anti-VEGFs i. Continuous ii. Categorical: <6, 6 to <12, 12 to <24, ≥24 months
- Specific anti-VEGF iii. Continuous (days)
- Time since wet Age-related macular degeneration (AMD) diagnosis [ Time Frame: 36-month period prior to the index date (inclusive of the index date) ( index date defined as the date of first brolucizumab injection) ]
Patients were measured at the eye level
- Time since any Age-related macular degeneration (AMD) diagnosis [ Time Frame: 36-month period prior to the index date (inclusive of the index date) ( index date defined as the date of first brolucizumab injection) ]
Patients were measured at the eye level
- Time from last anti-VEGF injection to index date [ Time Frame: 60 months prior to index ( index date defined as the date of first brolucizumab injection) ]
The following categories were measured:
- Continuous (days)
- Categorical (0-30, 31-60, 61-90, 91+ days)
- Number of ocular adverse events (AEs) [ Time Frame: Post-index period defined as the 180 days following therapy initiation, excluding index date ]
To assess the incidence of ocular AEs among patients treated with brolucizumab
|
